Literature DB >> 26702744

Combined Effect of Sodium Selenite and Ginsenoside Rh2 on HCT116 Human Colorectal Carcinoma Cells.

Changlai Zhu1, Fang Liu1, Wenbo Qian2, Tianyi Zhang2, Feng Li3.   

Abstract

BACKGROUND: Sodium selenite and ginsenoside Rh2 (G-Rh2) are well known for their anticancer properties and have been exploited as a new therapeutic approach. In this study, we are interested to evaluate if sodium selenite and G-Rh2 combination results in a synergistic anticancer effect that could contribute to lower systemic toxicity.
METHODS: We observed the synergistic antitumor effect by combination of sodium selenite and G-Rh2 on HCT-116 human colorectal carcinoma cells in vitro. Cell growth, viability, cell cycle progression and cell apoptosis, Bax/Bcl2 ratio, caspase-3 expression, reactive oxygen species (ROS) production and autophagy were evaluated.
RESULTS: The results showed that sodium selenite and G-Rh2 combination have a synergistic effect on cell growth inhibition (57%) compared with sodium selenite (25%) and G-Rh2 alone (28%) after 24 hours of treatment. This combination also induced G1 and S phase arrest simultaneously and increased apoptosis rate. The results also indicated that Bax/Bcl2 ratio and caspase-3 expression, known as proapoptotic factors, were increased in the presence of sodium selenite and G-Rh2 alone. However, combined drug treatment results in a more significant increase in Bax/Bcl2 ratio and caspase-3 expression (P < 0.05). In addition, this combination significantly induces a depletion of ROS production and autophagy, compared to control, sodium selenite and G-Rh2 alone (P < 0.05).
CONCLUSION: Sodium selenite and ginsenoside Rh2 combination may be a more effective treatment for human colorectal carcinoma and is a promising chemotherapeutic approach for malignant tumors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26702744     DOI: 0161901/AIM.005

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  7 in total

1.  Total ginsenosides of Chinese ginseng induces cell cycle arrest and apoptosis in colorectal carcinoma HT-29 cells.

Authors:  Ting Li; Wan Sun; Xiaoqiao Dong; Wenhua Yu; Jianyong Cai; Qiang Yuan; Letian Shan; Thomas Efferth
Journal:  Oncol Lett       Date:  2018-07-23       Impact factor: 2.967

2.  Paving the Road Toward Exploiting the Therapeutic Effects of Ginsenosides: An Emphasis on Autophagy and Endoplasmic Reticulum Stress.

Authors:  Milad Ashrafizadeh; Shima Tavakol; Reza Mohammadinejad; Zahra Ahmadi; Habib Yaribeygi; Tannaz Jamialahmadi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  20(s)-ginsenoside Rh2 promotes TRAIL-induced apoptosis by upregulating DR5 in human hepatocellular carcinoma cells.

Authors:  Wenmo Liu; Siqi Wang; Qinchuan Yang; Xinyao Feng; Bin Yu; Xianghui Yu
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

4.  Effects of G-Rh2 on mast cell-mediated anaphylaxis via AKT-Nrf2/NF-κB and MAPK-Nrf2/NF-κB pathways.

Authors:  Chang Xu; Liangchang Li; Chongyang Wang; Jingzhi Jiang; Li Li; Lianhua Zhu; Shan Jin; Zhehu Jin; Jung Joon Lee; Guanhao Li; Guanghai Yan
Journal:  J Ginseng Res       Date:  2021-10-13       Impact factor: 5.735

Review 5.  Saponins from Chinese Medicines as Anticancer Agents.

Authors:  Xiao-Huang Xu; Ting Li; Chi Man Vivienne Fong; Xiuping Chen; Xiao-Jia Chen; Yi-Tao Wang; Ming-Qing Huang; Jin-Jian Lu
Journal:  Molecules       Date:  2016-10-05       Impact factor: 4.411

6.  Ginsenoside Rh2 stimulates the production of mitochondrial reactive oxygen species and induces apoptosis of cervical cancer cells by inhibiting mitochondrial electron transfer chain complex.

Authors:  Ying Liu; Shiting Yu; Xin Xing; Juhui Qiao; Yiqiu Yin; Jiawen Wang; Meichen Liu; Wei Zhang
Journal:  Mol Med Rep       Date:  2021-10-29       Impact factor: 2.952

Review 7.  Role of ginsenosides in reactive oxygen species-mediated anticancer therapy.

Authors:  Islam M D Sodrul; Chenying Wang; Xiangfeng Chen; Jing Du; Hongxiang Sun
Journal:  Oncotarget       Date:  2017-12-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.